These findings reveal a critical tumour suppressor role for the JNK pathway in ER+ breast cancer and suggests that patients with deficient JNK signalling may derive limited benefit from combination endocrine therapy plus CDK4/6 inhibition. Here, CDK4 is linked to breast carcinoma.